Mengsi Zhou

Apr 21, 2024 | dovepress.com | Mengsi Zhou |Yanting Li |Liu Yang |Shuo Liu

IntroductionBreast cancer (BRCA) is the most frequently occurring malignancy and the primary cause of cancer-associated mortality among women, accounting for almost one-third of all newly diagnosed cancers in female patients in 2022.1,2 Despite tremendous efforts, the underlying molecular mechanisms of BRCA progression have remained elusive in recent years. The development of novel biomarkers for cancer diagnosis and prognosis is urgently required.